In vitro study of GDNF release from biodegradable PLGA microspheres.
暂无分享,去创建一个
Philippe Menei | Michelle Sergent | Emmanuel Garcion | Anne Clavreul | Jean-Pierre Benoit | Anne Aubert-Pouëssel | M. Sergent | J. Benoit | C. Montero-Menei | A. Clavreul | A. Aubert-Pouëssel | P. Menei | Marie-Claire Venier-Julienne | M. Venier-Julienne | Claudia N Montero-Menei | Christophe Jollivet | David C Bibby | C. Jollivet | D. Bibby | E. Garçion
[1] D. Volkin,et al. The adsorption of proteins to pharmaceutical container surfaces , 1992 .
[2] J. Benoit,et al. A Novel in Vitro Delivery System for Assessing the Biological Integrity of Protein upon Release from PLGA Microspheres , 2002, Pharmaceutical Research.
[3] J. Benoit,et al. Why Does PEG 400 Co-Encapsulation Improve NGF Stability and Release from PLGA Biodegradable Microspheres? , 1999, Pharmaceutical Research.
[4] Michael Sendtner,et al. Microencapsulated Ciliary Neurotrophic Factor: Physical Properties and Biological Activities , 1996, Experimental Neurology.
[5] Charles F. Morris,et al. Aggregation Pathway of Recombinant Human Keratinocyte Growth Factor and Its Stabilization , 1994, Pharmaceutical Research.
[6] Richard Grondin,et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.
[7] R. Almon,et al. ASSOCIATIONS OF BETA NERVE GROWTH FACTOR WITH BOVINE SERUM ALBUMIN AS WELL AS WITH THE ALPHA AND GAMMA SUBUNITS OF THE 7S MACROMOLECULE 1 , 1978, Journal of neurochemistry.
[8] I. Date,et al. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages , 2000, Neuroscience Research.
[9] L. Olson,et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[10] K. Çiftçi,et al. Formulation of Proteins and Peptides , 2005 .
[11] A. Klibanov,et al. Stability of Proteins and Their Delivery from Biodegradable Polymer Microspheres , 1996 .
[12] C. Svendsen,et al. Neurospheres modified to produce glial cell line‐derived neurotrophic factor increase the survival of transplanted dopamine neurons , 2002, Journal of neuroscience research.
[13] L. Olson,et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.
[14] A. Granholm,et al. A non‐invasive transport system for GDNF across the blood–brain barrier , 1997, Neuroreport.
[15] I. Strömberg,et al. Implantation of Bioactive Growth Factor-Secreting Rods Enhances Fetal Dopaminergic Graft Survival, Outgrowth Density, and Functional Recovery in a Rat Model of Parkinson's Disease , 2000, Experimental Neurology.
[16] B. Hoffer,et al. Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.
[17] N. Déglon,et al. Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[18] D. Brooks,et al. Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.
[19] Tracy Chen,et al. Formulation concerns of protein drugs , 1992 .
[20] W Wang,et al. Instability, stabilization, and formulation of liquid protein pharmaceuticals. , 1999, International journal of pharmaceutics.
[21] T. Hagg,et al. Glial cell line‐derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats , 1997, The Journal of comparative neurology.
[22] A. Björklund,et al. Sequential Administration of GDNF into the Substantia Nigra and Striatum Promotes Dopamine Neuron Survival and Axonal Sprouting but Not Striatal Reinnervation or Functional Recovery in the Partial 6-OHDA Lesion Model , 2000, Experimental Neurology.
[23] J. Benoit,et al. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. , 2004, Biomaterials.
[24] C. Spenger,et al. Implants of Polymer-Encapsulated Genetically Modified Cells Releasing Glial Cell Line-Derived Neurotrophic Factor Improve Survival, Growth, and Function of Fetal Dopaminergic Grafts , 1998, Experimental Neurology.
[25] Jean-Pierre Benoit,et al. Bovine serum albumin release from poly(α-hydroxy acid) microspheres: effects of polymer molecular weight and surface properties , 1997 .
[26] B. J. Baumgartner,et al. Neuroprotection of Spinal Motoneurons Following Targeted Transduction with an Adenoviral Vector Carrying the Gene for Glial Cell Line-Derived Neurotrophic Factor , 1998, Experimental Neurology.
[27] Smadar Cohen,et al. Microparticulate Systems for the Delivery of Proteins and Vaccines , 2020 .
[28] G. Gerhardt,et al. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys , 1999, Brain Research.
[29] Timothy Sendera,et al. Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.
[30] I. Fariñas,et al. Renal and neuronal abnormalities in mice lacking GDNF , 1996, Nature.
[31] C. Henderson,et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. , 1994, Science.
[32] F. Collins,et al. Purification and Initial Characterization of Rat B49 Glial Cell Line‐Derived Neurotrophic Factor , 1994, Journal of neurochemistry.
[33] S. Schwendeman,et al. Stabilization of Proteins Encapsulated in Cylindrical Poly(lactide-co-glycolide) Implants: Mechanism of Stabilization by Basic Additives , 2000, Pharmaceutical Research.
[34] D. Hilt,et al. Pharmacological Activities of Glial Cell Line-Derived Neurotrophic Factor (GDNF): Preclinical Development and Application to the Treatment of Parkinson's Disease , 1997, Experimental Neurology.
[35] Kinam Park,et al. Controlled drug delivery : challenges and strategies , 1997 .
[36] J. Benoit,et al. Development of microspheres for neurological disorders: from basics to clinical applications. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[37] J. Benoit,et al. NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[38] L. Olson,et al. The effect of glial cell line-derived neurotrophic factor in fibrin glue on developing dopamine neurons , 2004, Experimental Brain Research.
[39] H. Sah. Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[40] R. Borchardt,et al. Stability of Protein Pharmaceuticals , 1989, Pharmaceutical Research.
[41] J. Bloch,et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.
[42] E. Arenas,et al. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo , 1995, Neuron.
[43] D. Guilloteau,et al. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease , 2002, Synapse.
[44] J. Lile,et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.
[45] J. Benoit,et al. Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres. , 1993, Biomaterials.
[46] D. Yurek. Glial Cell Line-Derived Neurotrophic Factor Improves Survival of Dopaminergic Neurons in Transplants of Fetal Ventral Mesencephalic Tissue , 1998, Experimental Neurology.
[47] D. Maysinger,et al. In vitro effects of brain derived neurotrophic factor released from microspheres. , 1994, Neuroreport.
[48] M. Saarma,et al. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. , 2000, Science.